AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

A November 10 endocrinology news roundup reports that testosterone use among women has risen since 2016 and is often prescribed without a documented diagnosis of hypoactive sexual desire disorder (HSDD), its sole evidence-based indication. The roundup also notes FDA removal of certain boxed warnings from more hormone therapy patch labels and highlights several medication classes linked to bone density loss. Details such as the scale of prescribing, the specific patch products and the size of associated risks are not provided in the source summary.

Testosterone use among women has risen since 2016, and prescriptions are frequently issued without a documented diagnosis of hypoactive sexual desire disorder, according to a study cited in a November 10 endocrinology roundup. The report also noted that the FDA removed certain boxed warnings from labels for more menopausal hormone therapy patches, while several commonly used medication classes are linked to bone density loss.

Before you orderOffer from Amazon

Get workout gear delivered free with Prime

  • Fast, free delivery on millions of items
  • Prime Video, Amazon Music and more included
  • Member-only deals all year
Start your free Prime trial Free trial for eligible customers · Cancel anytime
As an affiliate, we earn on qualifying purchases.

The testosterone finding was reported in the Journal of Clinical Endocrinology & Metabolism, according to MedPage Today. The roundup describes HSDD as the sole evidence-based indication for testosterone use in women. It does not provide the study’s patient count, prescribing rate, or the size of the increase since 2016, so the scale and pattern of the change cannot be determined from the summary alone.

On menopause treatment, the roundup cited reporting by The Guardian that the FDA removed boxed warnings concerning cardiovascular disease, breast cancer and dementia from the prescribing information for additional hormone therapy patches. It did not name the products or specify when each label change took effect. Separately, the New York Times reported doctors’ warnings that certain hormone therapies may carry a small increase in breast cancer risk. The source does not identify the therapies or give a risk estimate.

The roundup also drew attention to drug-induced bone density loss. It listed oral corticosteroids, aromatase inhibitors, androgen deprivation therapy, anti-seizure medicines and selective serotonin reuptake inhibitors (SSRIs) as drug classes linked to loss of bone density. The summary does not quantify the risk for any class or say how dose, duration or patient characteristics affect it.

At a glance
reportWhen: Published November 10, 2026
The developmentA MedPage Today endocrinology roundup published November 10, 2026, highlighted rising testosterone use among women, FDA label changes for some hormone therapy patches and drug classes associated with bone density loss.

Prescribing and Safety Questions

Together, the items point to decisions patients and clinicians may face around hormone treatment and medication risks. The testosterone finding highlights a gap between a stated evidence-based indication and the diagnosis documented in many prescriptions, according to the cited study. It does not establish why clinicians prescribed the treatment or whether individual patients benefited.

The patch label changes and the separate warning about a small breast cancer risk are not necessarily contradictory: a boxed warning is a specific label measure, while the reported cancer risk concerns certain hormone therapies. Without the products, label language and underlying evidence, readers cannot tell how the changes apply to a particular treatment. The list of medicines associated with bone loss also underscores why patients should discuss long-term medication effects with a clinician rather than stop a prescribed drug on their own.

Products Worth Considering

Levoit Vital 200S-P Smart Air Purifier for Large Rooms (up to 1875 ft²)

Levoit Vital 200S-P Smart Air Purifier for Large Rooms (up to 1875 ft²)

As an affiliate, we earn on qualifying purchases.

The Roundup’s Three Health Updates

The source is a brief endocrinology news roundup, not a single clinical guideline or comprehensive review. It brings together findings and coverage from different publications: the testosterone study appeared in the Journal of Clinical Endocrinology & Metabolism, while the hormone patch and bone-loss items were attributed to news reports by The Guardian, the New York Times and the Washington Post.

Other items in the same roundup concerned diabetes remission, investigational treatment and industry news. Those developments are separate from the three hormone and bone-health topics covered here. The available source summary supplies no full study texts, regulator documents or detailed clinical recommendations, limiting what can be stated about methods and individual risk.

“The FDA removed boxed warnings about cardiovascular disease, breast cancer, and dementia from prescribing information for more hormone therapy patches.”

— MedPage Today, citing The Guardian

Missing Rates, Products and Risk Estimates

The source summary does not state how much testosterone prescribing increased, how many prescriptions lacked a documented HSDD diagnosis, or what period and patient groups the study examined. It also does not clarify whether prescribing without a documented diagnosis means the diagnosis was absent from the medical record or absent altogether.

For the FDA update, the patch names, timing and exact label changes remain unspecified. The reported small increase in breast cancer risk is not accompanied by an absolute or relative estimate, and the summary does not identify the particular therapies involved. For medication-associated bone loss, it provides no risk figures, dose or duration thresholds, or information about which patients are most affected. These omissions prevent product-specific or individual treatment conclusions.

Check Labels and Study Details

More detail would be needed from the full testosterone study and updated FDA prescribing information to establish the scale of the prescribing pattern and which patches are affected. Readers considering menopause treatment should discuss the specific product’s current label and its known benefits and risks with a qualified clinician. Patients taking medicines associated with bone loss should ask their prescriber whether their treatment and bone health need review; they should not change or stop medication without medical guidance.

Key Questions

What did the report say about testosterone use among women?

It said use has risen since 2016 and is frequently prescribed without a documented diagnosis of HSDD, described in the summary as the sole evidence-based indication. The source does not provide the size of the increase.

Which hormone patch warnings did the FDA remove?

The roundup says boxed warnings concerning cardiovascular disease, breast cancer and dementia were removed from prescribing information for more hormone therapy patches. It does not name the products or specify the revised label wording.

Does the patch update mean hormone therapy has no breast cancer risk?

No. The same roundup cited doctors warning of a small increase in breast cancer risk with certain hormone therapies. The summary does not identify those therapies or quantify the risk, so the label update should not be read as eliminating every risk.

Which medicines were linked to bone density loss?

The listed classes were oral corticosteroids, aromatase inhibitors, androgen deprivation therapy, anti-seizure medicines and SSRIs. The report gives no estimates of risk by drug, dose or duration.

Should patients stop a medicine because it may affect bone density?

No. The roundup does not recommend stopping treatment. Patients should discuss possible effects and any appropriate monitoring with their clinician before making changes to a prescribed medicine.

Source: medpagetoday.com

Wellness content on this site is informational and not a substitute for professional medical guidance.
You May Also Like

Why Workout Quality Matters More Than Device Quantity

A focus on workout quality over device quantity enhances effectiveness and safety, revealing why optimizing your routine is essential for real progress.

I Recommend This Yoga Practice To My Clients Who Are Desperate For Better Sleep

A yoga therapist recommends guided yoga nidra for relaxation and sleep support. Here is how it works, how to try it and who should seek advice first.

Should You Get A DEXA Scan At Menopause? What To Know About Bone Density Tests.

Exploring the benefits and considerations of bone density testing at menopause, including when a DEXA scan is recommended and what it reveals.

How I’ve Stopped Letting My Unhealed Parents Define My Worth

Exploring how individuals are redefining self-worth beyond unhealed parental influence amid rising wellness discussions.